var data={"title":"Acetazolamide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acetazolamide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5559?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acetazolamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acetazolamide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=acetazolamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Acetazolamide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129795\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Diamox Sequels [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129796\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acetazolam;</li>\n      <li>Diamox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129842\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Miscellaneous;</li>\n      <li>\n        Carbonic Anhydrase Inhibitor;</li>\n      <li>\n        Diuretic, Carbonic Anhydrase Inhibitor;</li>\n      <li>\n        Ophthalmic Agent, Antiglaucoma</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129800\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> IM administration is not recommended because of pain secondary to the alkaline pH.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Altitude illness:</b> Oral: Manufacturer's labeling: 500 to 1,000 mg/day in divided doses every 8 to 12 hours (immediate release tablets) or divided every 12 to 24 hours (extended release capsules). These doses are associated with more frequent and/or increased side effects. Alternative dosing has been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention:</i> 125 mg twice daily; beginning either the day before (preferred) or on the day of ascent; may be discontinued after staying at the same elevation for 2 to 3 days or if descent initiated (Basnyat 2006; Luks 2010). <b>Note:</b> In situations of rapid ascent (such as rescue or military operations), 1,000 mg/day is recommended by the manufacturer. The Wilderness Medical Society recommends consideration of using dexamethasone in addition to acetazolamide in these situations (Luks 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> 250 mg twice daily. <b>Note:</b> With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose (Luks 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edema:</b> Oral, IV: 250 to 375 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epilepsy:</b> Oral: 8 to 30 mg/kg/day in divided doses. A lower dosing range of 4 to 16 mg/kg/day in 1 to 4 divided doses has also been recommended; maximum dose: 30 mg/kg/day or 1 g/day (Oles 1989; Reiss 1996). <b>Note:</b> Minimal additional benefit with doses &gt;16 mg/kg/day. <b>Extended release capsule is not recommended for treatment of epilepsy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial periodic paralysis (off-label use): </b>Oral: 125 mg 3 times daily (Links 1988) <b>or</b> 250 mg once daily (Venance 2004) <b>or</b> 250 mg every 6 hours (Hoskins 1974). Additional data may be necessary to further define the role of acetazolamide in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glaucoma:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic simple (open-angle):</i> 250 mg 1 to 4 times/day or 500 mg extended release capsule twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Secondary or acute (closed-angle):</i> Initial: 250 to 500 mg; maintenance: 125 to 250 mg every 4 hours (250 mg every 12 hours has been effective in short-term treatment of some patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hydrocephalous, normal pressure (off-label use):</b> Oral: Initial: 125 mg/day; may increase dose up to 375 mg/day (Alperin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Metabolic alkalosis (off-label use):</b> IV: 500 mg as a single dose; reassess need based upon acid-base status (Marik 1991; Mazur 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of cystine renal calculi (adjunctive therapy) (off-label use): </b>Oral: 500 mg daily at bedtime in combination with potassium citrate and captopril (Sterrett 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Respiratory stimulant in stable hypercapnic COPD (off-label use):</b> Oral: 250 mg twice daily (Wagenaar 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129820\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=acetazolamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Acetazolamide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> IM administration is not recommended because of pain secondary to the alkaline pH.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edema</b>: Limited data available: Infants, Children, and Adolescents: Oral (immediate release), IV: 5 mg/kg/dose every other day in the morning (Pagliaro 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Epilepsy:</b> Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Altitude illness:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention:</i> 2.5 mg/kg/dose every 12 hours started either the day before (preferred) or on the day of ascent and may be discontinued after staying at the same elevation for 2-3 days or if descent initiated; maximum dose: 125 mg/dose (Luks 2010). <b>Note:</b> The International Society for Mountain Medicine does not recommend prophylaxis in children except in the rare circumstance of unavoidable rapid ascent or in children with known previous susceptibility to acute mountain sickness (Pollard 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> 2.5 mg/kg/dose every 8-12 hours; maximum dose: 250 mg/dose. <b>Note:</b> With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose (Luks 2010; Pollard 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129801\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Oral: Initial doses should begin at the low end of the dosage range. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129802\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable. Avoid use unless dose is reduced and serum concentrations can be monitored; monitor patients closely for CNS toxicity (Schwenk 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Supplemental dose is not necessary (Schwenk 1994).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671258\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in patients with cirrhosis or marked liver disease or dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129772\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 12 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diamox Sequels: 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129756\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129776\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered with food. May cause an alteration in taste, especially carbonated beverages. Short-acting tablets may be crushed and suspended in cherry or chocolate syrup to disguise the bitter taste of the drug; do not use fruit juices. Alternatively, submerge tablet in 10 mL of hot water and add 10 mL honey or syrup.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: IM administration is painful because of the alkaline pH of the drug; use by this route is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Direct IV injection is the preferred parenteral route of administration. Specific IV push rates are not provided in the manufacturer's labeling. However, an IV push rate of up to 500 mg over 3 minutes has been reported in a clinical trial (Mazur 1999). Additionally, a study to assess cerebrovascular reserve used a rapid IV push of up to 1 g over &le;1 minute (Piepgras 1990).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129775\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of glaucoma (chronic simple open-angle, secondary glaucoma, preoperatively in acute angle-closure); drug-induced edema or edema due to congestive heart failure (adjunctive therapy; IV and immediate release dosage forms); centrencephalic epilepsies (IV and immediate release dosage forms); prevention or amelioration of symptoms associated with acute mountain sickness (immediate and extended release dosage forms) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720644\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Familial periodic paralysis; Hydrocephalus, normal-pressure; Metabolic alkalosis; Prevention of cystine renal calculi (adjunctive therapy); Respiratory stimulant in stable hypercapnic COPD</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129850\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Acetazolamide may be confused with acetaminophen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Diamox [Canada and multiple international markets] may be confused with Diabinese brand name for chlorpropamide [Multiple international markets]; Dobutrex brand name for dobutamine [Multiple international markets]; Trimox brand name for amoxicillin [Brazil]; Zimox brand name for amoxicillin [Italy] and carbidopa/levodopa [Greece]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129763\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Ataxia, confusion, convulsions, depression, dizziness, drowsiness, excitement, fatigue, flaccid paralysis, headache, malaise, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Allergic skin reaction, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Electrolyte imbalance, growth retardation (children), hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, metabolic acidosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Decreased appetite, diarrhea, dysgeusia, glycosuria, melena, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Crystalluria, hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic and oncologic: Agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, cholestatic jaundice, fulminant hepatic necrosis, hepatic insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Myopia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Auditory disturbance, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Polyuria, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129780\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to acetazolamide, sulfonamides, or any component of the formulation; marked hepatic disease or insufficiency; decreased sodium and/or potassium levels; adrenocortical insufficiency; cirrhosis; hyperchloremic acidosis; severe renal disease or dysfunction; long-term use in noncongestive angle-closure glaucoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the FDA approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &ldquo;Warnings/Precautions&rdquo; for more detail.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129760\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Impairment of mental alertness and/or physical coordination may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory acidosis: Use with caution in patients with respiratory acidosis; may worsen acidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aspirin (high dose): Use with caution or avoid in patients taking high-dose aspirin concurrently; may lead to severe adverse effects including tachypnea, anorexia, lethargy, coma, and death. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to side effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Increasing the dose does not increase diuresis and may increase the incidence of drowsiness and/or paresthesia; often results in a reduction of diuresis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; IM administration: Painful because of the alkaline pH of the drug; use by this route is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129837\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129765\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9268&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): AcetaZOLAMIDE may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for osteomalacia or rickets may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Bicarbonate: AcetaZOLAMIDE may enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Carbonic Anhydrase Inhibitor Diuretics may decrease the serum concentration of Trientine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129768\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129783\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Limited data is available following the use of acetazolamide in pregnant women for the treatment of idiopathic intracranial hypertension (Falardeau 2013; Kesler 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to acetazolamide during pregnancy for the treatment of seizure disorders are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at aedpregnancyregistry.org</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10912707\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Acetazolamide is excreted into breast milk. In a case report, low concentrations of acetazolamide were detected in the breast milk and the infant serum following a maternal dose of acetazolamide 500 mg twice daily. Acetazolamide concentrations in the breast milk were 1.3 to 2.1 mcg/mL, 1 to 9 hours after the dose. Acetazolamide concentrations in the infant serum were 0.2 to 0.6 mcg/mL, 2 to 12 hours after nursing. Maternal plasma concentrations were 5.2 to 6.4 mcg/mL, 1 to 7 hours after the dose. All levels were obtained on days 4 to 5 of therapy, 10 days after delivery (S&ouml;derman 1984). Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129784\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with food to decrease GI upset. May have additive effects with other folic acid antagonists. Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129770\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure; serum electrolytes, periodic CBC with differential; monitor growth in pediatric patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129759\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversible inhibition of the enzyme carbonic anhydrase resulting in reduction of hydrogen ion secretion at renal tubule and an increased renal excretion of sodium, potassium, bicarbonate, and water. Decreases production of aqueous humor and inhibits carbonic anhydrase in central nervous system to retard abnormal and excessive discharge from CNS neurons.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129779\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Capsule (extended release): 2 hours; Tablet (immediate release): 1 to 1.5 hours; IV: 2 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Capsule (extended release): 8 to 18 hours; IV: 15 minutes; Tablet: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Inhibition of aqueous humor secretion: Capsule (extended release): 18 to 24 hours; IV: 4 to 5 hours; Tablet: 8 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Appears to be dose dependent; erratic with daily doses &gt;10 mg/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Erythrocytes, kidneys; blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life: 2.4 to 5.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Capsule (extended release): 3 to 6 hours; Tablet: 1 to 4 hours; IV: 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (70% to 100% [IV, tablet], 47% [extended release capsule] as unchanged drug within 24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129782\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, 12-hour</b> (AcetaZOLAMIDE ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $429.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (AcetaZOLAMIDE Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $49.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (AcetaZOLAMIDE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $217.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $288.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129785\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acemox (BD);</li>\n      <li>Acetadiazol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Acetak (PE);</li>\n      <li>Acetamide (LK);</li>\n      <li>Acetazol (KR);</li>\n      <li>Albox (JP);</li>\n      <li>Apo-Acetazolamide (MY);</li>\n      <li>Azol NCP (TW);</li>\n      <li>Azomid (ZA);</li>\n      <li>Carbinib (PT);</li>\n      <li>Cetamid (PH);</li>\n      <li>Defiltran (FR);</li>\n      <li>Diacarb (LV, RU, UA);</li>\n      <li>Diamox (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CO, CY, DK, EE, EG, FR, GB, GR, HK, HR, IE, IN, IQ, IR, IT, JO, JP, KR, KW, LB, LU, LY, MT, MY, NL, NO, NZ, OM, QA, RU, SA, SE, SG, SI, SK, SY, TH, VE, VN, YE, ZA);</li>\n      <li>Diamox Sustets (CO);</li>\n      <li>Diazomid (TR);</li>\n      <li>Diluran (CZ);</li>\n      <li>Diural (UY);</li>\n      <li>Diuramid (PL);</li>\n      <li>Diuremid (UA);</li>\n      <li>Edemox (ES);</li>\n      <li>Edimox (BD);</li>\n      <li>Evamox (PK);</li>\n      <li>Fonurit (HU);</li>\n      <li>Glaucomed (CO, EC);</li>\n      <li>Glaumox (AU, NZ);</li>\n      <li>Glaupax (CH, DE, HR, JP, TH);</li>\n      <li>Glauseta (ID);</li>\n      <li>Huma-Zolamide (HU);</li>\n      <li>Ledamox (JP);</li>\n      <li>Medene (TH);</li>\n      <li>Odemin (FI);</li>\n      <li>Optamide (PH);</li>\n      <li>Remox (BD);</li>\n      <li>Renamid (HR);</li>\n      <li>Stazol (PY);</li>\n      <li>Synomax (IN);</li>\n      <li>Theramox (BD);</li>\n      <li>Uramox (IL);</li>\n      <li>Zoladin (KR);</li>\n      <li>Zolmide (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acetazolamide injection [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals, Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acetazolamide tablets [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24634454\"></a>Alperin N, Oliu CJ, Bagci AM, et al. Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH. Neurology. 2014;82(15):1347-1351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/24634454/pubmed\" target=\"_blank\" id=\"24634454\">24634454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basnyat B, Gertsch JH,. Holck PS, et al, &ldquo;Acetazolamide 125 mg BD is Not Significantly Different from 375 mg BD in the Prevention of Acute Mountain Sickness: The Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial,&rdquo; <i>High Alt Med Biol</i>, 2006, 7(1):17-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/16544963/pubmed\" target=\"_blank\" id=\"16544963\">16544963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15303450/pubmed\" target=\"_blank\" id=\"15303450\">15303450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapron DJ, Gomolin IH, and Sweeney KR, &ldquo;Acetazolamide Blood Concentrations Are Excessive in the Elderly: Propensity for Acidosis and Relationship to Renal Function,&rdquo; <i>J Clin Pharmacol</i>, 1989, 29(4):348-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/2498399/pubmed\" target=\"_blank\" id=\"2498399\">2498399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapron DJ, Sweeney KR, Feig PU, et al, &ldquo;Influence of Advanced Age on the Disposition of Acetazolamide,&rdquo; <i>Br J Clin Pharmacol</i>, 1985, 19:363-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/3986087/pubmed\" target=\"_blank\" id=\"3986087\">3986087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falardeau J, Lobb BM, Golden S, et al, &quot;The Use of Acetazolamide During Pregnancy in Intracranial Hypertension Patients,&quot; <i>J Neuroophthalmol</i>, 2013, 33(1):9-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/22635167/pubmed\" target=\"_blank\" id=\"22635167\">22635167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hackett PH, Roach RC, &quot;High-Altitude Illness,&quot; <i>N Engl J Med</i>, 2001, 345(2):107-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/11450659/pubmed\" target=\"_blank\" id=\"11450659\">11450659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heller I, Halevy J, Cohen S, et al, &ldquo;Significant Metabolic Acidosis Induced by Acetazolamide,&rdquo; <i>Arch Intern Med</i>, 1985, 145(10):1815-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/4037942/pubmed\" target=\"_blank\" id=\"4037942\">4037942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoskins B, Maren TH, Vroom FQ, Jarrell MA. Acetazolamide and potassium flux in red blood cells. Studies in patients with hyperkalemic periodic paralysis. <i>Arch Neurol</i>. 1974;31(3):187-191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/4850386/pubmed\" target=\"_blank\" id=\"4850386\">4850386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15644481/pubmed\" target=\"_blank\" id=\"15644481\">15644481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kesler A and Kupferminc M, &quot;Idiopathic Intracranial Hypertension and Pregnancy,&quot; <i>Clin Obstet Gynecol</i>, 2013, 56(2):389-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/23563883/pubmed\" target=\"_blank\" id=\"23563883\">23563883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Links TP, Zwarts MJ, Oosterhuis HJ. Improvement of muscle strength in familial hypokalaemic periodic paralysis with acetazolamide. <i>J Neurol Neurosurg Psychiatry</i>. 1988;51(9):1142-1145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/3066848/pubmed\" target=\"_blank\" id=\"3066848\">3066848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luks AM, McIntosh SE, Grissom CK, et al, &ldquo;Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,&rdquo; <i>Wilderness Environ Med</i>, 2010, 21(2):146-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/20591379/pubmed\" target=\"_blank\" id=\"20591379\">20591379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1894525\"></a>Marik PE, Kussman BD, Lipman J, et al, &quot;Acetazolamide in the Treatment of Metabolic Alkalosis in Critically Ill Patients,&quot; <i>Heart Lung</i>, 1991, 20(5 Pt 1):455-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/1894525/pubmed\" target=\"_blank\" id=\"1894525\">1894525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10446816\"></a>Mazur JE, Devlin JW, Peters MJ, et al, &quot;Single Versus Multiple Doses of Acetazolamide for Metabolic Alkalosis in Critically Ill Medical Patients: A Randomized, Double-Blind Trial,&quot; <i>Crit Care Med</i>, 1999, 27(7):1257-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/10446816/pubmed\" target=\"_blank\" id=\"10446816\">10446816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moviat M, Pickkers P, van der Voort PH, et al, &ldquo;Acetazolamide-Mediated Decrease in Strong Ion Difference Accounts for the Correction of Metabolic Alkalosis in Critically Ill Patients,&rdquo; <i>Critical Care</i>, 2006, 10(1):R14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/16420662/pubmed\" target=\"_blank\" id=\"16420662\">16420662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oles KS, Penry JK, Cole DLW, et al, &ldquo;Use of Acetazolamide as an Adjunct to Carbamazepine in Refractory Partial Seizures,&rdquo; <i>Epilepsia</i>, 1989, 30(1):74-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/2492225/pubmed\" target=\"_blank\" id=\"2492225\">2492225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pagliaro LA and Pagliaro AM, eds. <i>Problems in Pediatric Drug Therapy. </i>4th ed. Washington, DC: American Pharmaceutical Association; 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parikh JR, Nolan RL, Bannerjee A, et al, &ldquo;Acetazolamide-Associated Nephrocalcinosis in a Transplant Kidney,&rdquo; <i>Transplantation</i>, 1995, 59(12):1742-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7604446/pubmed\" target=\"_blank\" id=\"7604446\">7604446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piepgras A, Schmiedek P, Leinsinger G, et al, &ldquo;A Simple Test to Assess Cerebrovascular Reserve Capacity Using Transcranial Doppler Sonography and Acetazolamide,&rdquo; <i>Stroke</i>, 1990, 21(9):1306-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/2204147/pubmed\" target=\"_blank\" id=\"2204147\">2204147</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollard AJ, Niermeyer S, Barry P, et al, &ldquo;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&rdquo; <i>High Alt Med Biol</i>, 2001, 2(3):389-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/11682018/pubmed\" target=\"_blank\" id=\"11682018\">11682018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiss WG and Oles KS, &ldquo;Acetazolamide in the Treatment of Seizures,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(5):514-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/8740334/pubmed\" target=\"_blank\" id=\"8740334\">8740334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rousseau P and Fuentevilla-Clifton A, &ldquo;Acetazolamide and Salicylate Interaction in the Elderly: A Case Report,&rdquo; <i>J Am Geriatr Soc</i>, 1993, 41(8):868-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/8340566/pubmed\" target=\"_blank\" id=\"8340566\">8340566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7999862\"></a>Schwenk MH, Blaustein DA, Wagner JD. The pharmacokinetics of acetazolamide during CAPD. <i>Adv Perit Dial.</i> 1994;10:44-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7999862/pubmed\" target=\"_blank\" id=\"7999862\">7999862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwenk MH, St. Peter WL, Meese MG, et al, &ldquo;Acetazolamide Toxicity and Pharmacokinetics in Patients Receiving Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(4):522-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7479208/pubmed\" target=\"_blank\" id=\"7479208\">7479208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shinnar S, Gammon K, Bergman EW Jr, et al, &ldquo;Management of Hydrocephalus in Infancy: Use of Acetazolamide and Furosemide to Avoid Cerebrospinal Fluid Shunts,&rdquo; <i>J Pediatr</i>, 1985, 107(1):31-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/4009338/pubmed\" target=\"_blank\" id=\"4009338\">4009338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15242722/pubmed\" target=\"_blank\" id=\"15242722\">15242722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&ouml;derman P, Hartvig P, and Fagerlund C, &quot;Acetazolamide Excretion Into Human Breast Milk,&quot; <i>Br J Clin Pharmacol</i>, 1984, 17(5):599-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/6733009/pubmed\" target=\"_blank\" id=\"6733009\">6733009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sterrett SP, Penniston KL, Wolf JS Jr, Nakada SY. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. <i>Urology</i>. 2008;72(2):278-281. doi: 10.1016/j.urology.2008.04.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/18533229/pubmed\" target=\"_blank\" id=\"18533229\">18533229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15373844/pubmed\" target=\"_blank\" id=\"15373844\">15373844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vaziri ND, Saiki J, Barton CH, et al, &ldquo;Hemodialyzability of Acetazolamide,&rdquo; <i>South Med J</i>, 1980, 73(4):422-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/7367929/pubmed\" target=\"_blank\" id=\"7367929\">7367929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venance SL, Jurkat-Rott K, Lehmann-Horn F, Tawil R. SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide. <i>Neurology</i>. 2004;63(10):1977.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/15557532/pubmed\" target=\"_blank\" id=\"15557532\">15557532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Wagenaar.2003\"></a>Wagenaar M, Vos P, Heijdra Y, et al, &ldquo;Comparison of Acetazolamide and Medroxyprogesterone as Respiratory Stimulants in Hypercapnic Patients With COPD,&rdquo; <i>Chest</i>, 2003, 123(5):1450-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wandstrat TL and Phillips J, &ldquo;Pseudotumor Cerebri Responsive to Acetazolamide,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(3):318.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss IS, &ldquo;Hirsutism After Chronic Administration of Acetazolamide,&rdquo; <i>Am J Ophthalmol</i>, 1974, 78(2):327-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-drug-information/abstract-text/4847470/pubmed\" target=\"_blank\" id=\"4847470\">4847470</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9268 Version 194.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F129795\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F129796\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F129842\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F129800\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F129820\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F129801\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F129802\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671258\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F129772\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F129756\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F129776\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F129775\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720644\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F129850\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F129763\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F129780\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F129760\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F129837\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F129765\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F129768\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F129783\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10912707\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F129784\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F129770\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F129759\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F129779\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F129782\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F129785\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9268|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acetazolamide-patient-drug-information\" class=\"drug drug_patient\">Acetazolamide: Patient drug information</a></li><li><a href=\"topic.htm?path=acetazolamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Acetazolamide: Pediatric drug information</a></li></ul></div></div>","javascript":null}